Metabolic Disorders and Delayed Diagnosis

Author(s):

Peter Toth, MD, PhD, FCCP, FESC, FAHA, FACC ,James Underberg, MS, MD, FACP, FACPM, FASPC, FASH, FNLA

Key Takeaways

Delayed FCS diagnosis can lead to exacerbated cardiovascular and metabolic consequences, increasing atherosclerosis and cardiovascular disease risk.
Persistent hypertriglyceridemia from untreated FCS may result in chronic pancreatitis, diabetes, and liver disease.
Early intervention is essential to manage triglyceride levels, prevent severe complications, and improve patient outcomes.

Panelists discuss the potential cardiovascular and metabolic consequences of a delayed diagnosis and treatment of Familial Chylomicronemia Syndrome (FCS), emphasizing the long-term health risks, including an increased risk of acute pancreatitis, cardiovascular disease, and metabolic complications.

EP: 1.Overview of FCS

EP: 2.Severe Hypertriglyceridemia

EP: 3.Pathophysiology of FCS

EP: 4.Early Diagnosis

EP: 5.Genetic Testing

Now Viewing

EP: 6.Metabolic Disorders and Delayed Diagnosis

Video content above is prompted by the following:

What are the potential cardiovascular and metabolic consequences associated with a delayed diagnosis and treatment of FCS?
What are the possible long-term consequences and health risks?